Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

THERAPY

Sarcoidosis: can tofacitinib slay the dragon?

Nature Reviews Rheumatology volume 18, pages 557–558 (2022)Cite this article

Subjects

Lack of understanding of the immunology of sarcoidosis has limited therapeutic progress. However, evidence from a small open-label trial suggests that treatment with the Janus kinase inhibitor tofacitinib can improve sarcoidosis symptoms, predominantly by inhibiting type 1 immunity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Damsky, W. et al. Inhibition of type 1 immunity with tofacitinib is associated with marked improvement in longstanding sarcoidosis. Nat. Commun. 13, 3140 (2022).

    Article  CAS  Google Scholar 

  2. Song, M. et al. Sarcoidosis and autoimmunity. Curr. Opin. Pulm. Med. 27, 448–454 (2021).

    Article  CAS  Google Scholar 

  3. Baughman, R. P. et al. ERS clinical practice guidelines on treatment of sarcoidosis. Eur. Respir. J. 58, 2004079 (2021).

    Article  CAS  Google Scholar 

  4. Sweiss, N. J. et al. C-reactive protein predicts response to infliximab in patients with chronic sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 27, 49–56 (2010).

    CAS  PubMed  Google Scholar 

  5. Iwasaki, T. et al. Dynamics of type I and type II interferon signature determines responsiveness to anti-TNF therapy in rheumatoid arthritis. Front. Immunol. https://doi.org/10.3389/fimmu.2022.901437 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Drent, M., Crouser, E. D. & Grunewald, J. Challenges of sarcoidosis and its management. N. Engl. J. Med. 385, 1018–1032 (2021).

    Article  CAS  Google Scholar 

  7. Schupp, J. C., Vukmirovic, M., Kaminski, N. & Prasse, A. Transcriptome profiles in sarcoidosis and their potential role in disease prediction. Curr. Opin. Pulm. Med. 23, 487–492 (2017).

    Article  CAS  Google Scholar 

  8. Sweiss, N. J. et al. Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry. PLoS One 6, e29126 (2011).

    Article  CAS  Google Scholar 

  9. Wyser, C. P., van Schalkwyk, E. M., Alheit, B., Bardin, P. G. & Joubert, J. R. Treatment of progressive pulmonary sarcoidosis with cyclosporin A. A randomized controlled trial. Am. J. Respir. Crit. Care Med. 156, 1371–1376 (1997).

    Article  CAS  Google Scholar 

  10. Sweiss, N. J. & Baughman, R. P. Tumor necrosis factor inhibition in the treatment of refractory sarcoidosis: slaying the dragon? J. Rheumatol. 34, 2129–2131 (2007).

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, University of Illinois, Chicago, IL, USA

    Nadera J. Sweiss

  2. Department of Medicine, University of Cincinnati, Cincinnati, OH, USA

    Robert Baughman

Authors
  1. Nadera J. Sweiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert Baughman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nadera J. Sweiss.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sweiss, N.J., Baughman, R. Sarcoidosis: can tofacitinib slay the dragon?. Nat Rev Rheumatol 18, 557–558 (2022). https://doi.org/10.1038/s41584-022-00832-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-022-00832-1

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing